Organization · Venture Capital
Incyte Venture Partners
Incyte Venture Partners is a San Antonio-based venture capital firm focused on early-stage investments in life sciences and medical technology, primarily in the Southeastern and Southwestern U.S.
Overview
What Incyte Venture Partners does
What Incyte Venture Partners is
Incyte Venture Partners is a San Antonio-based venture capital firm focused on early-stage investments in life sciences and medical technology, primarily in the Southeastern and Southwestern U.S.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Founded
- Founded in 2013
- Approximate age
- About 13 years
- Structured capabilities
- Funder
- Last reviewed
- April 22, 2026
Official channels
Find Incyte Venture Partners elsewhere
Open the official website or a supported primary organization account.
Capability profile
Incyte Venture Partners as a funder
Investment thesis
Early-stage medtech / life-science innovations that can shorten time and cost to market, improve clinical outcomes, and reduce overall healthcare cost.
Focus narrative
Incyte Venture Partners targets early-stage investments in life sciences and medical technology, with a particular focus on sectors such as medical devices, biotechnology, diagnostics, and specialty pharmaceuticals. The firm aims to back companies that are poised to make significant impacts in healthcare.
Value beyond capital
Incyte Venture Partners provides hands-on support to portfolio companies, leveraging the experience of its managers who have co-founded, managed, and exited multiple medical-technology firms. The firm focuses on reducing the time and cost to market for innovations while improving clinical outcomes.
Terms and economics
- Typical check
- $500,000–$1,500,000
Focus and fit
- Stages
- Pre-seed · Seed · Seed+ · Series A
- Sectors
- Biotech · Healthcare · Medical Devices · Diagnostics
- Regions
- United States
Availability
- Currently deploying
- Yes
Portfolio and track record
- Recorded portfolio count
- 31
- Recorded notable exits
- Vidacare, ENTrigue Surgical, Santalis Pharmaceuticals, NeoSurgical, and BiO2 Medical
Portfolio context
Aerin Medical: FDA-approved nasal breathing device. BioDtech: Endotoxin detection reagents, acquired by InventaBioTech. BiO2 Medical: Angel Catheter for PE prevention, acquired by Mermaid Medical Group. Bluegrass Vascular Technologies: Access catheter for venous access, raised $4.5M Series A. Cardiovate: Vascular tissue regeneration scaffold. DNAtrix: Oncolytic virus for brain cancer, EU Orphan designation. Xenex Disinfection Services: UV germicidal robots for hospitals.
Common questions
What to know about Incyte Venture Partners
Upseed classifies Incyte Venture Partners under the Venture Capital organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
April 22, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.